logo-loader
viewDiaMedica

Shares of DiaMedica Therapeutics rise after its chronic kidney disease drug seen as safe, well-tolerated

The Minneapolis biotech says the interim results came from a Phase 1b study of 28 patients

kidney
Chronic kidney disease is a progressive condition leading to the gradual loss of kidney function over time

Shares of DiaMedica Therapeutics Inc (NASDAQ:DMAC) jumped Thursday after the biotech reported that its drug DM199 was observed to be safe and well-tolerated in patients with chronic kidney disease.

The Minneapolis, Minnesota-based company said the interim results came from a Phase 1b study of 28 patients with moderate and severe chronic kidney disease. The results were consistent with earlier DM199 studies in healthy volunteers.

Following the announcement, DiaMedica’s stock increased 38% to $5.28 a share on heavy volume.

READ: Investors cheer ContraVir's positive results from a human-liver experiment using its CRV431 drug candidate

“The initial clinical data supports the expected mechanism of action for DM199,” said Dr Harry Alcorn Jr, chief medical officer at DiaMedica. “Most importantly, we’re encouraged about DM199’s potential as a treatment option to improve the lives of patients with chronic kidney disease.”

Chronic kidney disease is a progressive condition leading to the gradual loss of kidney function over time. Early stages of CKD may be present with few or no signs or symptoms and the majority of patients do not know they have kidney disease. DM199 is designed to lower the progression of the disease.

DM199 is currently being studied in a Phase 2 clinical study for acute ischemic stroke and the company is preparing to initiate Phase II clinical studies in patients with chronic kidney disease.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: DiaMedica

Price: 4.73 CAD

TSX-V:DMA
Market: TSX-V
Market Cap: $56.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Heritage Cannabis signs one-year deal with James E Wagner...

Heritage Cannabis (CSE: CANN) CEO Clint Sharples and James E Wagner Cultivation CEO Nathan Woodworth joined Steve Darling from Proactive to discuss their one year contract to work together to fill and pack a line of vape pen cartridges for the Canadian recreational and medical markets. Both...

1 hour, 16 minutes ago

2 min read